基本信息
浏览量:6
职业迁徙
个人简介
Dr. Yang’s research focuses on lung cancer treatment and the mechanism of multidrug resistance of chemotherapy or targeted therapy. His basic research work includes molecular mechanisms of resistance and reversal of resistance to chemotherapeutic agents and tyrosine kinase inhibitors. Dr. Yang is a leader in lung cancer clinical studies, especially in the development of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI). He and other Asian investigators have established EGFR TKI as the front line treatment for lung cancer patients with EGFR mutation (IPASS). He is also the global principal investigator of several pivotal trials that led to the global approval of a second generation EGFR TKI, afatinib (LUX-LUNG 1, 2 &3). An area of active research is now focused on the development of third generation EGFR TKIs and Dr. Yang has contributed to the approval of osimertinib.
研究兴趣
论文共 50 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
CANCER MEDICINEno. 1 (2024): n/a-n/a
Future oncology (London, England)no. 19 (2023): 1319-1329
引用0浏览0WOS引用
0
0
Cancersno. 20 (2023)
引用0浏览0WOS引用
0
0
JOURNAL OF THORACIC ONCOLOGYno. 12 (2023): 1743-1755
Cancer Discoveryno. 1 (2021): 74-89
引用0浏览0引用
0
0
Video Journal of Biomedicine (2021)
引用0浏览0引用
0
0
JTO clinical and research reportsno. 1 (2021): 100099
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn